ES2011319A6 - Procedimiento para preparar acidos piperacinacarboxilicos. - Google Patents

Procedimiento para preparar acidos piperacinacarboxilicos.

Info

Publication number
ES2011319A6
ES2011319A6 ES888800466A ES8800466A ES2011319A6 ES 2011319 A6 ES2011319 A6 ES 2011319A6 ES 888800466 A ES888800466 A ES 888800466A ES 8800466 A ES8800466 A ES 8800466A ES 2011319 A6 ES2011319 A6 ES 2011319A6
Authority
ES
Spain
Prior art keywords
piperazinecarboxylic acid
preparation
pharmaceutical compositions
compositions containing
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES888800466A
Other languages
English (en)
Spanish (es)
Inventor
Bernhard Aebischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of ES2011319A6 publication Critical patent/ES2011319A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES888800466A 1987-02-18 1988-02-18 Procedimiento para preparar acidos piperacinacarboxilicos. Expired - Lifetime ES2011319A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878703749A GB8703749D0 (en) 1987-02-18 1987-02-18 Piperazinecarboxylic acid

Publications (1)

Publication Number Publication Date
ES2011319A6 true ES2011319A6 (es) 1990-01-01

Family

ID=10612501

Family Applications (2)

Application Number Title Priority Date Filing Date
ES888800466A Expired - Lifetime ES2011319A6 (es) 1987-02-18 1988-02-18 Procedimiento para preparar acidos piperacinacarboxilicos.
ES8903482A Expired - Lifetime ES2021904A6 (es) 1987-02-18 1989-10-16 Procedimiento para preparar una composicion farmaceutica a base de un acido piperacinacarboxilico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES8903482A Expired - Lifetime ES2021904A6 (es) 1987-02-18 1989-10-16 Procedimiento para preparar una composicion farmaceutica a base de un acido piperacinacarboxilico.

Country Status (28)

Country Link
JP (1) JPH0723387B2 (fr)
KR (1) KR960015190B1 (fr)
AT (1) AT391320B (fr)
AU (1) AU613009B2 (fr)
BE (1) BE1002427A3 (fr)
CA (1) CA1327799C (fr)
CH (1) CH675125A5 (fr)
CY (1) CY1739A (fr)
DE (1) DE3804936C2 (fr)
DK (1) DK168441B1 (fr)
ES (2) ES2011319A6 (fr)
FI (1) FI86733C (fr)
FR (1) FR2610932B1 (fr)
GB (2) GB8703749D0 (fr)
GR (1) GR1002471B (fr)
HK (1) HK142093A (fr)
HU (2) HU199858B (fr)
IE (1) IE59098B1 (fr)
IL (1) IL85436A0 (fr)
IT (1) IT1219447B (fr)
LU (1) LU87129A1 (fr)
MY (1) MY103206A (fr)
NL (1) NL8800412A (fr)
NZ (1) NZ223529A (fr)
PH (1) PH25512A (fr)
PT (1) PT86776B (fr)
SE (1) SE467256B (fr)
ZA (1) ZA881146B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU202111B (en) * 1988-03-11 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing (r)-(e)-4--(3-phosphono-2-propenyl)-2-piperazine-carboxylic acid as active component
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
EP0488959A3 (en) * 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
US5260286A (en) * 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists
AU5693996A (en) * 1995-05-08 1996-11-29 Lonza A.G. Biotechnical production process of piperazine r-alpha-carbox ylic acids and piperazine s-alpha-carboxylic acid amide
EA001904B1 (ru) 1997-05-12 2001-10-22 ОРТО МакНЕЙЛ ФАРМАСЬЮТИКАЛ, ИНК. Арилзамещенные пиперазины для лечения доброкачественной гиперплазии простаты
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
JP2008124531A (ja) 2006-11-08 2008-05-29 Nec Electronics Corp 半導体装置およびオーディオプロセッサチップ
EP3427729A1 (fr) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probénécide destiné à être utilisé dans le traitement de maladies, troubles ou états épileptiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (fr) * 1984-04-17 1989-01-10 Jeffrey C. Watkins Derives de substitution en 4 d'acides piperazine-2- carboxyliques

Also Published As

Publication number Publication date
PT86776B (pt) 1992-05-29
IT8847631A0 (it) 1988-02-12
HU199858B (en) 1990-03-28
KR960015190B1 (ko) 1996-11-01
GB8803438D0 (en) 1988-03-16
GB2201676A (en) 1988-09-07
HK142093A (en) 1994-01-07
SE8800541A (fr) 1988-08-19
HU211269A9 (en) 1995-11-28
SE8800541D0 (sv) 1988-02-17
IL85436A (fr) 1992-12-01
NL8800412A (nl) 1988-09-16
AU613009B2 (en) 1991-07-25
GB8703749D0 (en) 1987-03-25
GR880100084A (el) 1988-12-16
HUT49361A (en) 1989-09-28
FR2610932A1 (fr) 1988-08-19
LU87129A1 (fr) 1988-09-20
AT391320B (de) 1990-09-25
CA1327799C (fr) 1994-03-15
PT86776A (pt) 1988-03-01
FI880744A0 (fi) 1988-02-17
JPS63203691A (ja) 1988-08-23
MY103206A (en) 1993-05-29
AU1175888A (en) 1988-08-25
JPH0723387B2 (ja) 1995-03-15
SE467256B (sv) 1992-06-22
DK168441B1 (da) 1994-03-28
IE59098B1 (en) 1994-01-12
GR1002471B (el) 1996-11-15
CH675125A5 (fr) 1990-08-31
DK79688A (da) 1988-08-19
BE1002427A3 (fr) 1991-02-05
NZ223529A (en) 1991-02-26
KR880009944A (ko) 1988-10-06
GB2201676B (en) 1991-01-02
ES2021904A6 (es) 1991-11-16
FI86733C (fi) 1992-10-12
CY1739A (en) 1995-10-20
FR2610932B1 (fr) 1990-11-16
DE3804936A1 (de) 1988-09-01
IL85436A0 (en) 1988-07-31
ATA36788A (de) 1990-03-15
ZA881146B (en) 1989-10-25
PH25512A (en) 1991-07-24
FI880744A (fi) 1988-08-19
DE3804936C2 (de) 1997-02-13
IT1219447B (it) 1990-05-18
FI86733B (fi) 1992-06-30
DK79688D0 (da) 1988-02-16
IE880413L (en) 1988-08-18

Similar Documents

Publication Publication Date Title
EP0592490A4 (en) Amino acid derivative anticonvulsant
GB8817585D0 (en) Improvements in/relating to apparatus for use in treatment of spinal disorders
PL298195A1 (en) Sulfonamido- and sulfonabidocabonyl-pyridine-2-carboxylic acid amides and their pyridine-n-oxides, method of obtaining them and their application as therapeutic agents as well therapeutic agents containing them and method of obtaining such therapeutic
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
GB8716925D0 (en) Apparatus for treatment of spinal disorders
IL83363A (en) Use of indol-3-yl-carboxylic acid endo-8-methyl-8-aza- bicyclo (3,2,1) oct-3-yl ester for the preparation of psycho-active pharmaceutical compositions suitable for the treatment of stress- related psychiatric disorders or for increasing vigilance
IL76454A0 (en) Diarylacetylenes,their preparation and pharmaceutical compositions containing them
AU2399892A (en) Treatment of anxiety disorders by nerve stimulation
ES2021904A6 (es) Procedimiento para preparar una composicion farmaceutica a base de un acido piperacinacarboxilico.
ES8705852A1 (es) Un procedimiento para la preparacion de nuevas benzamidas sustituidas
GB9418912D0 (en) Pharmaceutically active compounds
AU642428B2 (en) Method of treatment of CNS disorders and /or pain using gamma aminobutyric acid autoreceptor antagonists
IE880704L (en) Substituted benzamides.
EP0383171A3 (fr) Dérivés de 2,3,23 trihydroxy-urs-12-ène pour le traitement des troubles cognitifs
EP0273310A3 (fr) 5-Aryl-3H-1,2,4-triazol-3-ones et leur emploi comme anticonvulsifs
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
GB8808598D0 (en) Pharmaceutical compositions for treatment of prophylaxis of skin disorders
ZA883144B (en) Novel substituted silyl alkylene amines
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
HUT46921A (en) Process for producing 3-phenyl-7h-thiazolo /3,2-b//1,2,4/ triazin-7-ones, certain intermediaries thereof and pharmaceutics comprising such active ingredient
IL124730A0 (en) Compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of gastrointestinal disorders
IL124792A0 (en) Compositions containing bismuth and one or more antimicrobials for the prevention and treatment of gastrointestinal disorders
IL124729A (en) Use of bismuth for the manufacture of compositions for the treatment and prevention of gastrointestinal disorders
ES2007415A6 (es) Procewdimiento de obtencioon de citidina-difosfo-dimetiletanolamina.
Morizono et al. Experience in the treatment of shoulder-hand syndrome

Legal Events

Date Code Title Description
PC1A Transfer granted
FD2A Announcement of lapse in spain

Effective date: 20180802